Spero's Finnish-ing touch

While Spero Therapeutics LLC found its first antibiotic asset in its backyard, the biotech looked overseas for its newest program. The result is a deal for a portfolio of antibiotic potentiators plus a $30 million series A round with which to develop the molecules.

Spero in-licensed the preclinical compounds from Finnish biotech Northern Antibiotics Ltd. under undisclosed terms...